RET, NTRK, NRG1, and ROS1 Fusions as Targets in Lung Cancer
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer RET, ROS1, NTRK, and NRG1 fusions.
Transcript:
Hi there, I'm Dr Deborah Doroshow. I'm Assistant Professor of Medicine at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai here in New York City. I'm pleased to be here at GDU [Great Debates & Updates in Lung Cancer] in September 2023.
Today I have the honor to speak about 4 very rare fusions for patients who have lung cancer and they include RET, ROS1, NTRK, and NRG1. They are all found in only 1% to 2% of people who have non-small cell lung cancer but they all have multiple, very effective targeted therapies that are pills that can treat this disease and have patients have controlled disease for a prolonged period of time.
Even though they're very rare, the point of my talk was that its critical to look for them because we have lots of effective treatments for these patients.
Source:
Doroshow, D. Fusions as a Target in Lung Cancer: RET, NTRK, NRG1, ROS1. Presented at Great Debates & Updates in Lung Cancer; September 21-23; New York, NY.
